0 CHECKOUT

Oligodendroglioma - Pipeline Review, H1 2015

  • ID: 3164975
  • March 2015
  • 94 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Cavion LLC
  • Celgene Corporation
  • Eli Lilly and Company
  • e-Therapeutics plc
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • MORE

Oligodendroglioma - Pipeline Review, H1 2015

Summary

This, ‘Oligodendroglioma - Pipeline Review, H1 2015’, provides an overview of the Oligodendroglioma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Oligodendroglioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Oligodendroglioma and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Cavion LLC
  • Celgene Corporation
  • Eli Lilly and Company
  • e-Therapeutics plc
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Oligodendroglioma Overview
Therapeutics Development
Pipeline Products for Oligodendroglioma - Overview
Pipeline Products for Oligodendroglioma - Comparative Analysis
Oligodendroglioma - Therapeutics under Development by Companies
Oligodendroglioma - Therapeutics under Investigation by Universities/Institutes
Oligodendroglioma - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Oligodendroglioma - Products under Development by Companies
Oligodendroglioma - Products under Investigation by Universities/Institutes
Oligodendroglioma - Companies Involved in Therapeutics Development
Cavion LLC
Celgene Corporation
Celldex Therapeutics, Inc.
e-Therapeutics plc
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Millennium Pharmaceuticals, Inc.
Novartis AG
Orbus Therapeutics, Inc.
Sanofi
Tocagen Inc.
Oligodendroglioma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
alisertib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bevacizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CC-122 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dendritic Cell Therapy for Gliomas - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dendritic Cell Therapy for Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DNX-2401 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
eflornithine hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ETS-2101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
galunisertib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
mibefradil dihydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
panobinostat - Drug Profile
Product Description
Mechanism of Action
R&D Progress
plerixafor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rindopepimut - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Stem Cell Therapy for Glioma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
vocimagene amiretrorepvec + flucytosine ER - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oligodendroglioma - Recent Pipeline Updates
Oligodendroglioma - Dormant Projects
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Oligodendroglioma, H1 2015
Number of Products under Development for Oligodendroglioma - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Investigation by Universities/Institutes, H1 2015
Oligodendroglioma - Pipeline by Cavion LLC, H1 2015
Oligodendroglioma - Pipeline by Celgene Corporation, H1 2015
Oligodendroglioma - Pipeline by Celldex Therapeutics, Inc., H1 2015
Oligodendroglioma - Pipeline by e-Therapeutics plc, H1 2015
Oligodendroglioma - Pipeline by Eli Lilly and Company, H1 2015
Oligodendroglioma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015
Oligodendroglioma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015
Oligodendroglioma - Pipeline by Novartis AG, H1 2015
Oligodendroglioma - Pipeline by Orbus Therapeutics, Inc., H1 2015
Oligodendroglioma - Pipeline by Sanofi, H1 2015
Oligodendroglioma - Pipeline by Tocagen Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Assessment by Combination Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Oligodendroglioma Therapeutics - Recent Pipeline Updates, H1 2015
Oligodendroglioma - Dormant Projects, H1 2015

List of Figures
Number of Products under Development for Oligodendroglioma, H1 2015
Number of Products under Development for Oligodendroglioma - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

Cavion LLC
Celgene Corporation
Celldex Therapeutics, Inc.
e-Therapeutics plc
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Millennium Pharmaceuticals, Inc.
Novartis AG
Orbus Therapeutics, Inc.
Sanofi
Tocagen Inc.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Novartis AG
  • Qiagen N.V.
  • Elekta AB
  • Roche Diagnostics Ltd.
  • Bristol-Myers Squibb
  • Genentech, Inc.